Last update Oct. 12, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Rimonabant is also known as
Rimonabant in other languages or writings:
Rimonabant belongs to these groups or families:
|Oral Bioavail.||Baja - Low||%|
|T½||144 - 384||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an inverse agonist of the CB1 cannabinoid receptor. Used against obesity. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high percentage of protein binding make it highly unlikely that significant quantities will pass into breast milk.
Due to its serious side effects (anxiety, depression, suicidal ideation) it has been withdrawn from the market in most countries of the world. (Nguyen 2019, Moreira 2009)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)